Qualitative and quantitative determinations of pepsinogen I in gastric cancer and premalignant changes of the stomach.
Previous studies in rats have shown that stomach carcinogens cause a decrease of total pepsinogen content and a decrease of the fastest pepsinogen isozymogen in gastric mucosa before the appearance of carcinoma. In man the presence of Pg 5, and in particular a strong Pg 5, appears to be associated with gastric cancer. Low serum PG I levels were found in patients with gastric cancer, atrophic gastritis, intestinal metaplasia and gastric polyp. In this chapter we review the literature and report our results of PG I isozymogen and serum PG I determinations in 500 patients with various gastric disorders. It is concluded that premalignant changes of the stomach are associated with the presence of a strong Pg 5 isozymogen and with a low serum PG I level.
D005757:Gastritis, Atrophic / Q000097:blood; D006801:Humans; D008679:Metaplasia; D020116:Pepsinogen A; D010435:Pepsinogens / Q000032:analysis* / Q000097:blood / Q000235:genetics; D011127:Polyps / Q000097:blood; D011230:Precancerous Conditions / Q000378:metabolism*; D013272:Stomach Diseases / Q000097:blood / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000032:analysis* / Q000097:blood
D010435:Pepsinogens; D020116:Pepsinogen A